Lindman H, Taube A, Bergh J C
Department of Oncology, Akademiska Sjukhuset, University of Uppsala, Sweden.
Anticancer Res. 1994 Mar-Apr;14(2A):363-6.
Suramin at 100 to 800 micrograms/ml caused a dose dependent growth inhibition in three (Zr-75-1, BT 549 and HS-578T) parental human breast cancer cell lines and their corresponding sublines with acquired doxorubicin (dox) and multi-drug resistance. The effect was significantly more marked after 7 days suramin exposure compared with 3 days. The oestrogen and progesterone receptor rich cell line Zr-75-1 was more responsive to suramin compared with the other two lines. The sublines Zr-75-1-dox and HS-578T-dox with an increased expression of the permeability glycoprotein (P-gp) demonstrated a significantly decreased cell survival compared with corresponding parental cell lines at 3 and 7 days exposure of suramin, respectively. The subline BT 549-dox with multi-drug resistance without P-gp expression had a significantly impaired response after 3 days suramin compared with the parental line. These results indicate that suramin may be a potential therapeutic agent for the breast cancer patients with P-gp expression and multi-drug resistance.
100至800微克/毫升的苏拉明对三种（Zr-75-1、BT 549和HS-578T）亲代人乳腺癌细胞系及其相应的获得性阿霉素（阿霉素）和多药耐药亚系具有剂量依赖性生长抑制作用。与3天相比，苏拉明暴露7天后效果明显更显著。与其他两个细胞系相比，富含雌激素和孕激素受体的细胞系Zr-75-1对苏拉明更敏感。在苏拉明暴露3天和7天时，通透性糖蛋白（P-gp）表达增加的亚系Zr-75-1-dox和HS-578T-dox与相应的亲代细胞系相比，细胞存活率显著降低。具有多药耐药性且无P-gp表达的亚系BT 549-dox在苏拉明处理3天后与亲代细胞系相比反应明显受损。这些结果表明，苏拉明可能是治疗具有P-gp表达和多药耐药性的乳腺癌患者的潜在治疗剂。
